Recent advances in chemotherapy have interested many workers in treating a wide variety of diseases with the new drugs. None has received wider attention than sulfanilamide (paraaminobenzenesulfonamide). Following the reports of Long and Bliss1 that the drug was of value for the treatment of infections caused by streptococci, the work of Dees and Colston2 in first establishing its value in treating genital gonorrhea suggested that gonorrheal ophthalmia might also respond favorably.
Gonorrheal ophthalmia is most commonly seen in infants and comprises about 50 per cent of the cases of ophthalmia neonatorum. The introduction of the Credé method of prophylaxis reduced the incidence of the latter from approximately 10 per cent to well below 1 per cent.3 When this method is properly carried out, it is generally admitted that the actual incidence may be extremely low. In 1938 Skeel 4 reported 1 case of gonorrheal ophthalmia to every
BARBOUR FA, TOWSLEY HA. EXPERIENCE WITH SULFANILAMIDE IN TREATMENT OF GONORRHEAL OPHTHALMIA. Arch Ophthalmol. 1939;22(4):581–589. doi:https://doi.org/10.1001/archopht.1939.00860100065005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: